Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.

The ESMO regular abstract lift reveals first human datasets for several projects.

The group toplines a phase 2 win with Alphamedix.

Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.

The ESMO presidential session will feature data from Destiny-Breast05 and 11.

Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

Four more failed tiragolumab trials, including Imbrave-152, will feature.